专题发言: Abstract ID: 500 Outcome of patients with an ultralow risk 70-gene signature in the MINDACT trial.

10:40-10:47

巴蜀郡（宜宾+雅安厅）

乳腺癌专场2

专题发言: Abstract ID: 503 De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results.

10:47-10:54

巴蜀郡（宜宾+雅安厅）

乳腺癌专场2

专题发言: Abstract ID: 1003 Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: The sysucc-002 randomized clinical trial.

10:54-11:00

巴蜀郡（宜宾+雅安厅）

乳腺癌专场2